Covid-19 Antibody Race Is On as Glaxo and Vir Start Key Study

Published August 31, 2020

The race to find successful antibody treatments against Covid-19 is heating up as GlaxoSmithKline Plc and Vir Biotechnology Inc. start human trials to evaluate a potential drug that could be available as soon as the first half of next year.